FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_		. ,		IIIVESTITICITE		. ,	. 20 .0	_							
Name and Address of Reporting Person*  Kumar Ramesh						2. Issuer Name <b>and</b> Ticker or Trading Symbol Onconova Therapeutics, Inc. [ ONTX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Itamar	Tturresir													X Dire	ctor			10% Ov	vner	
(Last) (First) (Middle)						Date of Earliest Transaction (Month/Day/Year)								X Offi belo		give title		Other (s below)	specify	
C/O ONCONOVA THERAPEUTICS, INC.							02/23/2018							President and CEO						
375 PHEASANT RUN																				
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) NEWTO	WN PA	A	18940											X Form filed by One Reporting Pe					n	
					-									Form filed by More than One Reporting Person					ting	
(City)	(S	State) (Zip)																		
		Tal	ole I - Nor	n-Deriv	vativ	e Se	curitie	s Ac	quired, I	Disp	osed of	f, or Ber	neficial	ly Own	ed					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		, Transaction Disposed Code (Instr. 5)		ties Acquired (A) d Of (D) (Instr. 3, 4				ly	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a		tion(s)			(iiisti. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
		1		· • · ·		Can	·	_	•	<u> </u>		1								
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares							
Stock Option (right to purchase)	\$1.09	02/23/2018			A		73,220		02/23/2018 <sup>(</sup>	1) (	)2/23/2028	Common Stock	73,220	\$0		73,220		D		

## Explanation of Responses:

1. This option grant was made in lieu of cash payment for a portion of Dr. Kumar's year-end bonus. The options vest immediately.

/s/ Ramesh Kumar

02/27/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.